It's been nearly two years since Elevidys, a gene therapy for Duchenne MD developed by Sarepta Therapeutics, was approved by ...

WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that ... scientists about its effectiveness in treating Duchenne muscular ...

Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a ...

John Brandsema, MD, a pediatric neurologist at Children’s Hospital of Philadelphia, speaks with Healio about the latest ...

“There are no disease-modifying treatments approved for patients with any subtype of limb-girdle muscular dystrophy ... of research and development, Sarepta Therapeutics.

April 04, 2025--(BUSINESS WIRE)--Sarepta Therapeutics ... rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. Following the safety update on acute liver failure ...

April 15, 2025--(BUSINESS WIRE)--Sarepta Therapeutics ... updates from its clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5, 2D/R3, and 2E/R4.

Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...